Dry Eye Disease Market to Register Immense Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading Companies – BRIM, Ocular, Iacta, AbbVie, Novartis, Kowa, Sylentis, Palatin, Yuyu, Mimetogen

Advertisement

Several approved therapies drive the current therapeutic landscape of dry eye disease in the 7MM. The dry eye disease market is estimated to increase by 2032. The major reason for this besides the approved products will be the launch of emerging therapies, during the forecast period (2023–2032).

New York, USA, Dec. 07, 2023 (GLOBE NEWSWIRE) — Dry Eye Disease Market to Register Immense Growth During the Study Period (2019–2032), Estimates DelveInsight | Leading Companies – BRIM, Ocular, Iacta, AbbVie, Novartis, Kowa, Sylentis, Palatin, Yuyu, Mimetogen 

Several approved therapies drive the current therapeutic landscape of dry eye disease in the 7MM. The dry eye disease market is estimated to increase by 2032. The major reason for this besides the approved products will be the launch of emerging therapies, during the forecast period (2023–2032). 

Advertisement

DelveInsight’s Dry Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of individual therapies, and current and forecasted dry eye disease market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Dry Eye Disease Market Report

  • As per DelveInsight’s analysis, the dry eye disease market is anticipated to grow at a significant CAGR by 2032.
  • According to DelveInsight’s analysis, in 2022, females account for a higher number of dry Eye disease cases than males in the US.
  • Leading dry eye disease companies such as BRIM Biotechnology Inc., Ocular Therapeutix, Inc., Iacta Pharmaceuticals, AbbVie, Novartis Pharmaceuticals, Kowa Research Institute, Inc., Sylentis, S.A., Dompé Farmaceutici S.p.A, Aerie Pharmaceuticals, Palatin Technologies, Inc, Yuyu Pharma, Inc., Mimetogen Pharmaceuticals USA, Inc., and others are developing novel dry eye disease drugs that can be available in the dry eye disease market in the coming years.
  • Some of the key therapies for dry eye disease treatment include BRM421, OTX-DED, IC265, ABBV-444, Lifitegrast, K-161, Tivanisiran sodium, Oxervate, AR-15512, PL9643, YP-P10, Tavilermide, and others. 

Discover which therapies are expected to grab the dry eye disease market share @ Dry Eye Disease Market Report

Dry Eye Disease Overview

Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a prevalent condition characterized by insufficient tear production or rapid tear evaporation. Tears play a vital role in lubricating and nourishing the eyes, and when lacking, DED can result in dryness, redness, swelling, and irritation. Dry eye disease causes include reduced tear production, excessive tear evaporation, and abnormalities in mucus or lipid production. Common dry eye disease symptoms encompass a dry, gritty sensation, burning, itching, a feeling of a foreign body, excessive tearing, eye pain, redness, and occasional photophobia. Environmental factors such as low humidity and high temperatures can exacerbate symptoms, leading to complications like tiny eye abrasions. In advanced cases, the epithelium undergoes pathological changes, including squamous metaplasia and loss of goblet cells.

Dry Eye Disease Epidemiology Segmentation

The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The dry eye disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalent Cases of Dry Eye Disease 
  • Total Diagnosed Prevalent Cases of Dry Eye Disease
  • Type-specific Diagnosed Prevalent Cases of Dry Eye Disease
  • Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease
  • Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease
  • Age-specific Diagnosed Prevalent Cases of Dry Eye Disease
  • Treated Cases of Dry Eye Disease

Download the report to understand which factors are driving dry eye disease epidemiology trends @ Dry Eye Disease Epidemiological Insights

Dry Eye Disease Treatment Market 

The management strategies for dry eye disease are diverse. The primary objectives of dry eye disease treatment include alleviating dry eye symptoms, enhancing patient comfort, restoring the normal state of the ocular surface and tear film, and, where possible, preventing corneal damage. Dry eye disease treatment modalities span a spectrum from patient education, environmental or dietary adjustments, and the use of artificial tear substitutes to the insertion of punctual plugs, as well as the administration of topical and/or systemic anti-inflammatory medications. In certain cases, surgical interventions may also be considered. Traditionally, dry eye disease was attributed mainly to tear insufficiency, prompting treatments involving tear replacement products or the conservation of tears through punctual plugs. However, contemporary approaches now encompass methods designed to stimulate tear production.

In May 2023, the US FDA granted approval for Bausch and Lomb’s MIEBO (perfluorohexyloctane ophthalmic solution) to treat the signs and symptoms of dry eye disease. This milestone marks the first FDA-approved eye drop specifically designed to address tear evaporation rather than tear formation. Developed by Novaliq, Bausch + Lomb secured exclusive licensing rights in the US back in 2019. Perfluorohexyloctane, a key component of the drug, creates a monolayer at the air-liquid interface of the tear film, with the anticipated benefit of reducing evaporation.

Learn more about the FDA-approved drugs for dry eye disease @ Drugs for Dry Eye Disease Treatment 

Key Dry Eye Disease Therapies and Companies

  • BRM421: BRIM Biotechnology Inc.
  • OTX-DED: Ocular Therapeutix, Inc.
  • IC265: Iacta Pharmaceuticals
  • ABBV-444: AbbVie
  • Lifitegrast: Novartis Pharmaceuticals
  • K-161: Kowa Research Institute, Inc.
  • Tivanisiran sodium: Sylentis, S.A.
  • Oxervate: Dompé Farmaceutici S.p.A
  • AR-15512: Aerie Pharmaceuticals
  • PL9643: Palatin Technologies, Inc
  • YP-P10: Yuyu Pharma, Inc.
  • Tavilermide: Mimetogen Pharmaceuticals USA, Inc.

To know more about dry eye disease clinical trials, visit @ Dry Eye Disease Treatment Drugs 

Dry Eye Disease Market Dynamics

The dry eye disease market dynamics are anticipated to change in the coming years. As an increasingly recognized ocular health concern, the dry eye disease market is witnessing a surge in research and development activities aimed at introducing innovative therapies. Lifestyle changes, prolonged screen time, and environmental factors contribute to the rising incidence of dry eye disease, expanding the potential consumer base for related pharmaceuticals and treatments. Furthermore, the dry eye disease market is shaped by a growing awareness among healthcare professionals and patients, leading to early diagnosis and intervention. The competition among pharmaceutical companies to develop effective and convenient treatment modalities, such as novel eye drops or sustained-release formulations, adds an element of dynamism to the dry eye disease market.

Furthermore, many potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the dry eye disease market in the 7MM.

However, several factors may impede the growth of the dry eye disease market. Regulatory hurdles pose a significant challenge, as the approval process for new treatments requires rigorous testing and compliance with stringent standards. The complexity of ocular physiology and the need for targeted drug delivery systems present scientific challenges, requiring substantial investment in research and development. Additionally, the crowded landscape of ocular health products and treatments demands a robust differentiation strategy for new entrants. 

Moreover, dry eye disease treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the dry eye disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the dry eye disease market growth.

Dry Eye Disease Report Metrics Details
Study Period 2019–2032
Dry Eye Disease Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Dry Eye Disease Companies BRIM Biotechnology Inc., Ocular Therapeutix, Inc., Iacta Pharmaceuticals, AbbVie, Novartis Pharmaceuticals, Kowa Research Institute, Inc., Sylentis, S.A., Dompé Farmaceutici S.p.A, Aerie Pharmaceuticals, Palatin Technologies, Inc, Yuyu Pharma, Inc., Mimetogen Pharmaceuticals USA, Inc., and others
Key Dry Eye Disease Therapies BRM421, OTX-DED, IC265, ABBV-444, Lifitegrast, K-161, Tivanisiran sodium, Oxervate, AR-15512, PL9643, YP-P10, Tavilermide, and others

Scope of the Dry Eye Disease Market Report

  • Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and emerging therapies
  • Dry Eye Disease Market Dynamics: Attribute Analysis of Emerging Dry Eye Disease Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement

Discover more about dry eye disease drugs in development @ Dry Eye Disease Clinical Trials

Table of Contents

1. Dry Eye Disease Market Key Insights
2. Dry Eye Disease Market Report Introduction
3. Dry Eye Disease Market Overview at a Glance
4. Dry Eye Disease Market Executive Summary
5. Disease Background and Overview
6. Dry Eye Disease Treatment and Management
7. Dry Eye Disease Epidemiology and Patient Population
8. Patient Journey
9. Dry Eye Disease Marketed Drugs
10. Dry Eye Disease Emerging Drugs
11. Seven Major Dry Eye Disease Market Analysis
12. Dry Eye Disease Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Dry Eye Disease Epidemiology Forecast

Dry Eye Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted dry eye disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dry Eye Disease Pipeline

Dry Eye Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dry eye disease companies, including Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech, Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa,  among others.

Moderate Dry Eye Market

Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate dry eye companies, including Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, among others.

Mild Dry Eye Market

Mild Dry Eye Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mild dry eye companies, including Aramis Biosciences, Dreamhawk Vision Biotech, Inc., Taejoon Pharmaceutical, Quorum Innovations, among others.

Severe Dry Eye Market

Severe Dry Eye Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe dry eye companies, including Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

CONTACT: Contact Us Shruti Thakur  [email protected]  +1(919)321-6187  www.delveinsight.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.